Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo

New therapies for glioblastoma (GBM) are needed, as five-year survival is <10%. The proteasome inhibitor marizomib (MRZ) has inhibitory and death-inducing properties unique from previous inhibitors such as bortezomib (BTZ), and has not been well examined in GBM. We evaluated the mechanism of deat...

Descripción completa

Detalles Bibliográficos
Autores principales: Manton, Christa A., Johnson, Blake, Singh, Melissa, Bailey, Cavan P., Bouchier-Hayes, Lisa, Chandra, Joya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4726202/
https://www.ncbi.nlm.nih.gov/pubmed/26804704
http://dx.doi.org/10.1038/srep18953

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4726202/
https://www.ncbi.nlm.nih.gov/pubmed/26804704
http://dx.doi.org/10.1038/srep18953

Ejemplares similares